PDF(Pubmed)
Abstract：
UNASSIGNED: There has been an increasing awareness of the effects of combining bromocriptine-QR with other medications for diabetes mellitus type 2. This study aimed to assess the efficacy and safety of bromocriptine-QR as an adjunctive therapy for patients with uncontrolled type 2 diabetes mellitus.
UNASSIGNED: This systematic review is registered at the International Prospective Register of Systematic Reviews (CRD42022360326). Literature search was done via MEDLINE, NCBI, Google Scholar, Science Direct, Europe PMC and Cochrane Library databases. We included randomized controlled trials with participants 18 years old and above with uncontrolled type 2 diabetes mellitus. The primary outcome of interest is the efficacy and safety of bromocriptine-QR as an adjunctive therapy for glycemic control. Case reports, case series, reviews and animal studies were excluded. The risk of bias was reviewed using the Cochrane Risk of Bias tool. Meta-analysis was performed using Review Manager 5.4 and presented as a weighted mean difference and 95% confidence interval for changes from the baseline level.
UNASSIGNED: Nine studies were included in the systematic review with a total of 2709 participants. The baseline HbA1c in the bromocriptine-QR group was 7.42% and 7.51% in the control group. The bromocriptine-QR group was favoured, outperforming the control group in terms of reducing hemoglobin A1c(HbA1c), with a statistically significant difference (weighted mean difference -0.6%; 95% CI [-0.83,-0.36]; p<0.00001). The most common side effects were nausea (33.75% vs 6.92%), fatigue (13.11% vs 5.94%), and headache (11.17% vs 6.87%).
UNASSIGNED: Administration of bromocriptine-QR at a dose range of 1.6 to 4.8 mg/day as an adjunctive therapy reduced HbA1c and FBG in patients with uncontrolled type 2 diabetes mellitus (T2DM). However, there were also statistically greater odds of the occurrence of adverse events such as nausea, vomiting, and headache compared to controls.
UNASSIGNED: This systematic review is registered at the International Prospective Register of Systematic Reviews (CRD42022360326). Literature search was done via MEDLINE, NCBI, Google Scholar, Science Direct, Europe PMC and Cochrane Library databases. We included randomized controlled trials with participants 18 years old and above with uncontrolled type 2 diabetes mellitus. The primary outcome of interest is the efficacy and safety of bromocriptine-QR as an adjunctive therapy for glycemic control. Case reports, case series, reviews and animal studies were excluded. The risk of bias was reviewed using the Cochrane Risk of Bias tool. Meta-analysis was performed using Review Manager 5.4 and presented as a weighted mean difference and 95% confidence interval for changes from the baseline level.
UNASSIGNED: Nine studies were included in the systematic review with a total of 2709 participants. The baseline HbA1c in the bromocriptine-QR group was 7.42% and 7.51% in the control group. The bromocriptine-QR group was favoured, outperforming the control group in terms of reducing hemoglobin A1c(HbA1c), with a statistically significant difference (weighted mean difference -0.6%; 95% CI [-0.83,-0.36]; p<0.00001). The most common side effects were nausea (33.75% vs 6.92%), fatigue (13.11% vs 5.94%), and headache (11.17% vs 6.87%).
UNASSIGNED: Administration of bromocriptine-QR at a dose range of 1.6 to 4.8 mg/day as an adjunctive therapy reduced HbA1c and FBG in patients with uncontrolled type 2 diabetes mellitus (T2DM). However, there were also statistically greater odds of the occurrence of adverse events such as nausea, vomiting, and headache compared to controls.
摘要：
■人们越来越意识到溴隐亭-QR与其他药物联合治疗2型糖尿病的效果。本研究旨在评估溴隐亭-QR作为未控制的2型糖尿病患者的辅助治疗的有效性和安全性。
■本系统评价在国际系统评价前瞻性注册中心（CRD4202236326）注册。文献检索是通过MEDLINE完成的，NCBI,谷歌学者，科学直接，欧洲PMC和Cochrane图书馆数据库。我们纳入了18岁及以上未控制的2型糖尿病患者的随机对照试验。感兴趣的主要结果是溴隐亭-QR作为血糖控制的辅助疗法的有效性和安全性。病例报告,案例系列,综述和动物研究被排除.使用Cochrane偏差风险工具审查了偏差风险。使用ReviewManager5.4进行荟萃分析，并以基线水平变化的加权平均差和95％置信区间表示。
■9项研究纳入系统评价，共有2709名参与者。溴隐亭-QR组的基线HbA1c为7.42%，对照组为7.51%。溴隐亭-QR组受到青睐，在降低血红蛋白A1c（HbA1c）方面优于对照组，差异有统计学意义（加权平均差-0.6%；95%CI[-0.83，-0.36]；p<0.00001）。最常见的副作用是恶心（33.75%vs6.92%），疲劳(13.11%对5.94%)，头痛(11.17%vs6.87%)。
■以1.6至4.8mg/天的剂量范围给予溴隐亭-QR作为辅助治疗可降低未控制的2型糖尿病（T2DM）患者的HbA1c和FBG。然而,在统计学上也有更大的发生不良事件的几率，如恶心，呕吐,与对照组相比，头痛。
■本系统评价在国际系统评价前瞻性注册中心（CRD4202236326）注册。文献检索是通过MEDLINE完成的，NCBI,谷歌学者，科学直接，欧洲PMC和Cochrane图书馆数据库。我们纳入了18岁及以上未控制的2型糖尿病患者的随机对照试验。感兴趣的主要结果是溴隐亭-QR作为血糖控制的辅助疗法的有效性和安全性。病例报告,案例系列,综述和动物研究被排除.使用Cochrane偏差风险工具审查了偏差风险。使用ReviewManager5.4进行荟萃分析，并以基线水平变化的加权平均差和95％置信区间表示。
■9项研究纳入系统评价，共有2709名参与者。溴隐亭-QR组的基线HbA1c为7.42%，对照组为7.51%。溴隐亭-QR组受到青睐，在降低血红蛋白A1c（HbA1c）方面优于对照组，差异有统计学意义（加权平均差-0.6%；95%CI[-0.83，-0.36]；p<0.00001）。最常见的副作用是恶心（33.75%vs6.92%），疲劳(13.11%对5.94%)，头痛(11.17%vs6.87%)。
■以1.6至4.8mg/天的剂量范围给予溴隐亭-QR作为辅助治疗可降低未控制的2型糖尿病（T2DM）患者的HbA1c和FBG。然而,在统计学上也有更大的发生不良事件的几率，如恶心，呕吐,与对照组相比，头痛。
